Defining the role of anti-epileptic pharmacogenetics in psychiatric drug therapy

Dennis J. Dlugos, Russell J. Buono, Thomas N. Ferraro

Research output: Contribution to journalReview articlepeer-review


Although it is not yet possible to make general recommendations for the incorporation of genetic data into the decision making process for anti-epileptic drug therapy, recent studies are beginning to provide a foundation for the future establishment of treatment guidelines. Data from these studies can be used to refine candidate gene hypotheses for possible confirmation in independent populations treated with traditional anti-epileptic drugs and can also help to inform study design for the investigation of newer drugs as well. Documentation of the clinical relevance of variation in genes encoding drug target (SCN1A), drug transport (ABCB1), and drug metabolizing (CYP2C9, CYP2C19) proteins strengthens the rationale for future studies and provides clues for better integrating genetic information into psychiatric pharmacotherapy. In order to begin to address the key questions pertaining to genetics and anti-epileptic drug therapy, future studies must combine pharmacokinetic data with standardized clinical outcome measures of efficacy and tolerability. This will better help to define the relationship between gene variation and the clinical use of anti-epileptic drugs and will provide the most rational treatment options for patients with psychiatric disorders and epilepsy.

Original languageEnglish (US)
Pages (from-to)389-393
Number of pages5
JournalPsychiatric Annals
Issue number6
StatePublished - Jun 2008
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health


Dive into the research topics of 'Defining the role of anti-epileptic pharmacogenetics in psychiatric drug therapy'. Together they form a unique fingerprint.

Cite this